Compare · NVO vs TPST
NVO vs TPST
Side-by-side comparison of Novo Nordisk A/S (NVO) and Tempest Therapeutics Inc. (TPST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and TPST operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $207.76B, about 11819.7x TPST ($17.6M).
- Over the past year, NVO is down 16.7% and TPST is down 90.3% - NVO leads by 73.7 points.
- NVO has been more active in the news (9 items in the past 4 weeks vs 8 for TPST).
- NVO has more recent analyst coverage (25 ratings vs 7 for TPST).
- Company
- Novo Nordisk A/S
- Tempest Therapeutics Inc.
- Price
- $46.93+0.43%
- $1.03-4.17%
- Market cap
- $207.76B
- $17.6M
- 1M return
- -3.79%
- +8.63%
- 1Y return
- -16.67%
- -90.33%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 9
- 8
- Recent ratings
- 25
- 7
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Tempest Therapeutics Inc.
Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha, and is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company is headquartered in South San Francisco, California.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Berenberg
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
Latest TPST
- SEC Form 8-K filed by Tempest Therapeutics Inc.
- SEC Form S-1 filed by Tempest Therapeutics Inc.
- SEC Form DEFA14A filed by Tempest Therapeutics Inc.
- Tempest Therapeutics Inc. filed SEC Form 8-K: Other Events
- SEC Form 10-Q filed by Tempest Therapeutics Inc.
- Tempest Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Tempest Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities
- Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update
- SEC Form DEFA14A filed by Tempest Therapeutics Inc.
- Tempest Therapeutics Inc. filed SEC Form 8-K: Other Events